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ARTICLE OPEN
Language disturbances in schizophrenia: the relation with
antipsychotic medication
J. N. de Boer 1,2✉, A. E. Voppel2, S. G. Brederoo2, F. N. K. Wijnen 3 and I. E. C. Sommer2
Language disturbances are key aberrations in schizophrenia. Little is known about the influence of antipsychotic medication on
these symptoms. Using computational language methods, this study evaluated the impact of high versus low dopamine D2
receptor (D2R) occupancy antipsychotics on language disturbances in 41 patients with schizophrenia, relative to 40 healthy
controls. Patients with high versus low D2R occupancy antipsychotics differed by total number of words and type-token ratio,
suggesting medication effects. Both patient groups differed from the healthy controls on percentage of time speaking and clauses
per utterance, suggesting illness effects. Overall, more severe negative language disturbances (i.e. slower articulation rate, increased
pausing, and shorter utterances) were seen in the patients that used high D2R occupancy antipsychotics, while less prominent
disturbances were seen in low D2R occupancy patients. Language analyses successfully predicted drug type (sensitivity= 80.0%,
specificity= 76.5%). Several language disturbances were more related to drug type and dose, than to other psychotic symptoms,
suggesting that language disturbances may be aggravated by high D2R antipsychotics. This negative impact of high D2R
occupancy drugs may have clinical implications, as impaired language production predicts functional outcome and degrades the
quality of life.
npj Schizophrenia            (2020) 6:24 ; https://doi.org/10.1038/s41537-020-00114-3
INTRODUCTION
Disorder language is a hallmark feature of schizophrenia. Varying
degrees of aberrant language can be observed in up to 80% of
patients with schizophrenia1, and have been shown to comprise a
broad variety of abnormalities in semantics, syntax, and phonol-
ogy2–5. Most common among these are poverty of speech (alogia),
increased pausing, reduced variation in intonation (monotone
speech), and disturbances in the (discursive) coherence, such as
derailment and tangentiality6–8. Since language is of primary
importance for social relations and daily interactions9, it is a
worrisome observation that language is affected in this patient
group, as patients with schizophrenia are known to experience
difficulties in maintaining trustworthy relations with others9 and
are at an increased risk of social isolation10. Language distur-
bances in schizophrenia may negatively impact social relations in
several ways. For example, reduced speech rate is known to
negatively influence judgments of the speaker by others. Slower
speakers are considered less truthful, less fluent, and less
persuasive11,12. Disturbances in spontaneous speech can therefore
have a negative impact on a broad range of life experiences13.
Moreover, abnormalities of language in schizophrenia are
predictive of functional outcome14,15, have a negative impact on
both objective and subjective quality of life16, and thus greatly
impact rehabilitation.
Antipsychotics are considered the first choice of treatment for
schizophrenia, with positive effects reported on hallucinations,
delusions, and disorganization17–19. However, little is known about
the remedying effects of antipsychotic medication on language
disturbances. Importantly, there is reason to assume that
antipsychotic drugs may contribute to some of these language
perturbations20,21. Specifically, antipsychotic drugs’ effects on
dopamine receptors can be hypothesized to impair language, in
several ways.
Firstly, negative language symptoms with a cognitive basis,
such as poverty of speech and incoherence, are likely to be
affected by antipsychotic medication, since antipsychotic drugs
potentially increase these symptoms by blocking dopamine
receptors in prefrontal brain areas that are thought to be
hypodopaminergic in patients with a psychosis22–24.
Secondly, binding to the striatal dopamine receptor is known to
cause extrapyramidal side effects (EPS), such as tremor, bradyki-
nesia and rigidity25,26. Although EPS are classically known as limb
movement disturbances, they also affect the motor components
of spoken language production, i.e., the programming and
execution of articulatory movements27. Indeed, drug-induced
EPS, or severe Parkinsonism, is characterized by slow, hesitant and
soft speech, indicating that medication affects planning and
controlling of articulatory movements27.
While all antipsychotic drugs block the dopamine D2 receptor
(D2R), some do so quite extensively and others more subtly. They
can be classified based on their mechanism of action. For
example, clozapine and quetiapine bind more loosely to the
D2R than dopamine itself (henceforth low D2R occupancy
drugs)28. By contrast, typical antipsychotics such as haloperidol
and risperidone are “strong” D2R antagonists (henceforth high
D2R occupancy drugs), as they bind more tightly to the receptor
than dopamine. It can, therefore, be expected that not all types of
antipsychotic medication will have similar effects on language
production. Rather, the extent to which the medication binds to
dopamine receptors may play a vital role in this.
Language production involves at least three processing
systems: the conceptualizer, the formulator and the articulator29.
Conceptualizing involves the organizing of ideas and intentions
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into a preverbal message. The formulator translates this preverbal
message into a linguistic structure with its corresponding meaning
and form. Finally, articulation involves the programming and
execution of a predetermined phonetic plan by the muscles of the
articulatory tract. The processing systems involved in language
production can therefore also be categorized as being either
primarily cognitive (conceptualizer and formulator) or motoric
(articulator) in nature. Language production is thus a shared
motoric and cognitive process, and is therefore likely to be
affected by dopamine blockage in both striatal as well as
prefrontal brain areas.
Previous studies assessing language and speech in schizo-
phrenia revealed that at the level of speech delivery, proportion of
spoken time and speech rate are decreased, and (clause initial)
pauses are increased30–32. As regards language structure and
content, research indicates that syntactic complexity is
decreased6, which is reflected in short sentences with reduced
embedding and limited lexical diversity. Furthermore, schizophre-
nia patients suffer from word-finding issues (mostly related to
content words such as nouns or verbs), resulting in longer pauses
and disfluencies6.
Summarizing, language disturbances are a core symptom of
schizophrenia, which greatly impacts social and functional
outcomes and quality of life. Little is known about the impact of
antipsychotic medication on language in patients with schizo-
phrenia. As EPS can negatively affect the articulatory system (i.e.,
programming and execution of articulatory movements), and
brain areas implicated in the cognitive components of language
production (conceptualizing and formulating) are known to be
negatively affected by antipsychotic drugs that block dopamine
receptors, such drugs may have a relatively negative impact on
spoken language in schizophrenia patients. From the above
follows the hypothesis that language will be more severely
disturbed (e.g. increased pauses and slower speech rate) in
patients with schizophrenia that use high D2R occupancy
medication than in those using low D2R occupancy medication.
In the present study, we set out to test this hypothesis by
comparing spoken language samples of schizophrenia patients on
language variables that are known to be disturbed in schizo-
phrenia6,30,31,33 (see Table 1 for an overview). Patients were
divided into two categories based on dopamine binding profiles,
namely patients with low D2R occupancy drugs (i.e. quetiapine,
paliperidone, olanzapine, and clozapine) or high D2R occupancy
drugs (i.e. aripiprazole, risperidone, flupentixol, amisulpride, and
haloperidol). We additionally analyzed language produced by a
healthy control group for comparison and explored the relation
with psychotic symptom severity.
RESULTS
Demographics
Clinical and demographic data are shown in Table 2. The groups
did not differ with regard to sex and age. Patients had received
less education than healthy controls, and there was no difference
in parental education level between groups. Symptom severity as
measured by the Positive And Negative Syndrome Scale (PANSS)
as well as drug dose as measured in chlorpromazine equivalent
dose did not differ between patients with high or low D2R
occupancy medication.
Language variables between the groups
For an overview of the language variables, see Fig. 1 and Table 1.
Schizophrenia patients with high versus low D2R occupancy
medication and healthy controls were compared on language
variables using a MANCOVA.
To correct for the influence of age, sex, and education level on
normal variation in language, these variables were entered as
covariates in the model. The MANCOVA revealed a main effect of
group status on language (Pillai’s trace= 0.526, F (2, 80) = 1.843,
Table 1. Description of language variables.
Variable Definition/calculation Measures
Total number of words Total words produced in the interview Indicative of poverty of speech.
Articulation rate Syllables/phonation time (Motor) speed in speech production.
Average pause duration Total time the participant was pausing in
seconds/number of pauses
Pauses often reflect formulating or planning language and might
therefore reflect processing speed.
Average turn duration Average duration of a speaking turn in
seconds
Average length of an answer, before another question is necessary.
Percentage of time speaking Time participant speaking/time
interviewer speaking*100
Might reflect spontaneity in speech or willingness to speak.
Mean length of
utterance (MLU)
Mean length of utterance in morphemes Sentence complexity. Greater length indicates more complex sentences.
Type-token ratio (TTR) # types/# tokens Lexical diversity. Types: the number of different words used in the sample.
Tokens: all words in the sample. This number goes from 0.001 to 1.0. Low
values indicate a lot of repetition, high values means each word in the
sample was different. High TTR indicates fewer syntactical structures.
Clauses per utterance Average number of clauses per
utterances
Grammatical complexity. More clauses per utterance indicate more
syntactical complex sentences.
Noun verb ratio # nouns/# verbs Number of nouns per verbs. Might reflect specific difficulty with either
nouns or verbs.
Open–closed ratio # open class words/# closed class words Content words versus function words. Open class: content words. Word
class accepts new members easily. Closed class: function words. Word
class does not easily accept new members. Might reflect specific difficulty
with either content or function words.
Disfluencies # of disfluencies/# all words Difficulties formulating sentences. All forms of disfluencies, including
filled pauses and retracing as a percentage of all words.
Pause to word ratio # pauses/# all words Indication of processing speed. Measures how many pauses are needed
to formulate one word.
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p= 0.016, partial η2= 0.263). Furthermore, a main negative effect
was found for age (Pillai’s trace= 0.328, F (1, 80) = 2.477, p=
0.010, partial η2= 0.328) and male sex (Pillai’s trace= 0.395, F(1,
80) = 3.315, p= 0.001, partial η2= 0.395), but not for education
level. No interaction effects were found between the independent
variables. Post-hoc tests revealed that patients that use high D2R
occupancy drugs differ from low D2R occupancy patients on a
number of language variables, including total number of words
and type-token ratio (TTR, i.e. a measure for lexical diversity), as
well as from healthy controls on several language variables,
including articulation rate, TTR, mean length of utterance (MLU).
However, low D2R occupancy patients do not differ from healthy
controls on most aspects of language (see Table 3).
Relation with antipsychotic medication
A binary logistic regression model was used to investigate
whether language variables could predict whether patients used
a high or low D2R occupancy drug. Drug dosage was entered as a
covariate. The optimal model had high predictive power (Nagelk-
erke approximation of R2= 0.560), and the Hosmer-Lemeshow
test for goodness-of-fit was non-significant (p= 0.932). The
following language variables were included in the final model:
mean pause duration, MLU, TTR, and speaking turn duration.
Patients with high and low D2R occupancy could be classified with
this model with a sensitivity of 80.0% and a specificity of 76.5%.
Relation with antipsychotic medication and psychotic symptoms
To assess the effects of medication type and dose as well as
psychotic symptoms, multivariate linear regression analyses were
performed for each of the language variables. Psychotic symp-
toms, drug type (high or low D2R drugs) and drug dosage were
entered as predictors. Unstandardized (B) and standardized (β)
regression coefficients for each predictor in the separate models
as well as the predictive utility of the entire model are reported in
Table 4. The models for noun verb ratio and percentage of
disfluencies were not significant. The variance in pause duration
and the number of clauses per utterance were predicted solely by
aspects of medication use (D2R occupancy for both, and dosage
for pause duration). Speaking turn duration was only predicted by
PANSS positive. Articulation rate, percentage of time speaking,
MLU, TTR, and pause to word ratio were found to be affected by
both symptoms and D2R occupancy.
Table 2. Demographic characteristics of patients with schizophrenia with high 2DR occupancy medication, low D2R occupancy medication, and
healthy controls.
High D2R Low D2R HC Test statistic p-value
n 23 18 40
Sex, male: female, n 17:6 14:4 36:4 χ2= 3.038 0.219
Age, mean (SD) 28.5 (9.04) 28.3 (9.39) 31.7 (11.71) F(2,78)= 1.002 0.372
Years of education, mean (SD) 13.2 (2.63) 12.2 (2.94) 14.8 (2.20) F(2,77)= 7.446 0.001
Parental years of education, mean (SD) 12.7 (2.93) 12.3 (2.85) 12.8 (3.10) F(2,68)= 0.128 0.880
Self-reported language fluency, n
Fluent in Dutch only 13 15 19 χ2= 7.357 0.118
Fluent in two languages 9 3 17
Fluent in three language 1 0 4
Duration of illness years, mean (SD) 4.5 (5.55) 5.1 (7.49) MW= 189 0.871
Total PANSS, mean (SD) 52.0 (11.98) 52.1 (8.57) F(1,39)= 0.002 0.963
PANSS positive 10.7 (4.72) 11.2 (2.98) F(1,39)= 0.136 0.714
PANSS negative 14.0 (5.12) 14.9 (4.96) F(1,39)= 0.313 0.579
PANSS general 27.3 (6.51) 26.1 (4.95) F(1,39)= 0.424 0.519
Psychotic disorder, n χ2= 4.244 0.236
Schizophrenia 8 5
Schizoaffective disorder 4 3
Schizophreniform disorder 0 3
Psychosis NOS 12 7











SD standard deviation, n sample size, High D2R schizophrenia patients with high dopamine D2 receptor occupancy medication, Low D2R schizophrenia
patients with low dopamine D2 receptor occupancy medication, HC healthy controls, PANSS positive and negative syndrome scale, NOS not otherwise
specified, MW Mann–Whitney U.
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DISCUSSION
Using computational language and speech analysis tools, this
study evaluated the impact of antipsychotic medication type (high
versus low D2R occupancy) on language disturbances in schizo-
phrenia. We showed that patients who use high D2R occupancy
drugs, such as aripiprazole, haloperidol, and risperidone, differ
from patients who use low D2R occupancy drugs on total number
of words and TTR, suggesting an effect of medication. Both patient
groups differ from healthy controls on percentage of time
speaking and clauses per utterance, suggesting illness effects.
Overall, patients who use high D2R occupancy drugs have more
severe negative language disturbances (i.e. slower articulation
rate, increased and prolonged pauses and shorter utterances with
fewer clauses), while less prominent disturbances are seen in
patients who use low D2R occupancy drugs, such as clozapine and
olanzapine. Language analyses were successful in predicting
whether the recorded discourse belonged to a patient using high
versus low D2R drugs. Finally, various language disturbances
(MLU, TTR, pause to word ratio and clauses per utterance) were
related to the use of high D2R occupancy drugs and the dosage of
those drugs, rather than to the severity of the psychotic
symptoms, which again suggests medication effects over illness
effects.
As hypothesized, our results demonstrate that the use of high
D2R occupancy drugs is associated with more severe language
disturbances in schizophrenia compared to low D2R occupancy
drugs, as reflected by reduced language production (i.e. total
number of words produced) compared to low D2R occupancy
drugs. Clinically, this might be described as alogia or poverty of
speech, which is considered a negative symptom. This is most
likely related to an increased hypodopaminergic state in the
prefrontal cortex, as medication-induced decrease of dopamine in
the prefrontal cortex impairs cognitive functioning in general and
induces negative symptoms34,35.
Our results further demonstrated that patients who use high
D2R occupancy drugs differ from healthy controls on several
language parameters (pause duration, MLU, clauses per utterance,
pause to word ratio), while low D2R occupancy patients do not or
to a lesser degree. We interpret these results as indicative of two
individual mechanisms of action. On the one hand, the finding
that high D2R occupancy drugs are associated with increased
pause rate, pause duration and reduced clauses per utterance,
may be related to disturbances in language processing. Informa-
tion transfer between prefrontal and temporal language-relevant
regions is crucial for efficient language production36,37. A recent
study by our group revealed that integrity of white-matter
language pathways is associated with broad language distur-
bances in schizophrenia38. High D2R occupancy drugs may induce
a hypodopaminergic stage and reduce information processing in
language tracts, and thus give rise to language disturbances
related to cognitive fluency or efficiency (i.e. pauses) and cognitive
effort or complexity (i.e. MLU, clauses per utterance, TTR). Indeed,
previous research in schizophrenia has shown that hypodopami-
nergic states are associated with white-matter integrity in the
frontal cortex39. Moreover, dopamine replacement therapy in
Parkinson’s disease is associated with both increased connectivity
in white-matter language pathways improved and speech
production40. On the other hand, patients using high D2R
occupancy drugs spoke more slowly than controls (i.e. articulation
rate), which can be related to blockage of the extrapyramidal
system which has a slowing effect on articulation. In like manner,
patients with Parkinson’s disease show a characteristic pattern of
declining speech and articulation rate with illness progression41–43.
Our finding that high D2R occupancy drugs (such as
risperidone) are associated with increased pausing, provides
evidence that increased pausing is not related to sedative effects
of antipsychotic drugs. Many of the low D2R occupancy drugs are
highly sedating (e.g. olanzapine, quetiapine and clozapine), which
is known to negatively influence cognitive performance44; instead
we found increased pausing to be associated with less sedative
antipsychotics.
A key question is whether the relative increase in language
disturbances is caused by the use of high D2R occupancy drugs
and should thus be regarded an adverse effect, or whether
language disturbances in schizophrenia are relatively more severe
in the high D2R occupancy group because they are better
suppressed by low D2R occupancy drugs. The design of the
current study does not allow for a discrimination between these
mechanisms of action. Language disturbances are present in
children who later develop psychosis45 and in youths at clinical
high risk for psychosis3,46,47, in the absence of antipsychotic
exposure, and are associated with the severity of psychotic
symptoms in this group48. Moreover, language disturbances are
also present in patients with bipolar disorder that do not use
antipsychotic medication49–51. Within the small existing literature
base dedicated to this topic, there is some evidence that language
disturbances respond well to antipsychotic medication (haloper-
idol)52. Indeed, some have suggested that antipsychotic medica-
tion improves communication since it is associated with reduced
incoherence and tangentiality53. However, there is also some
evidence that antipsychotics reduce intelligibility of speech and
induce poverty of speech20,21. Antipsychotics can also cause acute
laryngeal dystonia54 or laryngeal dyskinesia55, causing stridor and
thereby negatively impacting speech. Furthermore, in Hunting-
ton’s disease56, research shows that antipsychotic medication
decreases speech rate and induces excessive loudness and pitch
deviations. In contrast, dopamine replacement therapy in
Parkinson’s disease has positive effects on speech tempo and
Fig. 1 Illustration of the interview and language measures. The speech waves (oscillograms) are for illustrative purposes only and do not
reflect the actual recordings of these sentences.
J.N.de Boer et al.
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prosody57. It is important to bear in mind that the field is in its
early stages and our results are preliminary, and corresponding
interpretations should, therefore, be regarded with caution.
Moreover, not all language disturbances are the same; alogia, flat
intonation (both negative symptoms), highly associated or
incoherent language (both positive symptoms) might all be
considered aberrant language production; however, the mental
processes underlying these aberrations clearly differ. Therefore,
the effects of antipsychotic medication on these language
aberrations may differ as well. Replication in a larger sample is
needed to fully understand the complex relation between
language and antipsychotic medication.
The main limitations of this study include the absence of
medication naïve or medication-free patients as well as a
nonpsychotic patient group with antipsychotics, which precluded
a pure assessment of the influence of antipsychotic medication on
language production. Further, because a cross-sectional design
was used, medication usage was not randomized and the
language disturbances we observed could not be followed over
time. Moreover, we could not rule out a bias in prescribing
patterns of high and low D2R occupancy drugs, although clinical
guidelines do not express any preference between antipsychotic
drugs (except for clozapine). For this reason, a causal relation with
the use of medication could not be established. Due to the design,
we were unable to meaningfully examine the impact of
neuropsychological deficits or other confounding variables (e.g.,
premorbid functioning, rapport, as well as illness-related factors
such as sleep dysfunction, depression and paranoia) on language
production. This remains an important topic for future research. It
should be noted that we found an increased TTR in the patients as
compared to the healthy controls. This is most likely an effect of
sample size (total number of words produced), since the patients
produced less words in total and TTR is known to be higher for
smaller speech samples58. Furthermore, it is important to note that
a large part of our high D2R occupancy patients used aripiprazole
(65%). As stated above, aripiprazole is categorized as a strong D2R
antagonist, although it also has some agonistic effects59. A related
issue is that clozapine was grouped into the low D2R occupancy
group, while clozapine is in general reserved for treatment of
refractory patients with schizophrenia. Thus, replication in a large
independent sample will be an important future research
direction, in order to have sufficient statistical power to address
the effects of each of the drugs individually. Of note, in the current
study, we only evaluated the effects of dopaminergic receptor
occupancy while most antipsychotic drugs also act on other
neurotransmitter systems (e.g. serotonergic and anticholinergic
receptors). For example, anticholinergic medication has been
shown to negatively impact spoken language by inducing dryness
of the oral and nasal mucosa60. Further research is needed to
unravel the effects of these neurotransmitters on language
disturbances. It should be noted that although no significant
differences in language fluency were found between the groups,
bilingualism is an important confounder in language research in
schizophrenia. Ethnic minority groups in Western countries have
an increased risk of developing schizophrenia, and more
specifically linguistic distance to the majority language has been
associated with increased psychosis risk61. Given the small sample
size, this factor could not be fully explored in the current study,
therefore further research is needed to assess the influence of
bilingualism on language in schizophrenia.
We recognize and appreciate that there are several other
approaches to quantify language disturbance in schizophrenia33.
In the last decade, natural language processing analyses,
specifically semantic space analyses and phonetic or prosodic
methods, have been applied to language production in schizo-
phrenia62–66. These are important developments that merit a
future study designed to address the potential effects of
medication on these specific analyses.
Our findings have several implications. First, as language is a
highly important source of information in the psychiatric
evaluative process, clinicians should be aware that poverty of
speech in patients might be at least partly an effect of (highly
dopaminergic) medication. Deteriorated language may, therefore,
not necessarily be a sign of active psychosis. Second, since many
schizophrenia patients require sustained pharmacological treat-
ment to prevent relapses, research on language disturbances has
been performed mostly in participants that are on antipsychotic
Table 3. Language characteristics of patients with schizophrenia with high 2DR occupancy medication, low D2R occupancy medication, and healthy
controls.







Mean ± SE Mean ± SE Mean ± SE F-statistic p-value A vs B B vs C A vs C
Total number of words 1043.0 ± 113.60 1485.6 ± 140.56 1768.9 ± 101.18 11.544 <0.0001** 0.025* – <0.0001**
Articulation rate 5.5 ± 0.20 5.9 ± 0.25 6.2 ± 0.18 3.156 0.049* – – 0.017*
Pause duration (s) 1.03 ± 0.043 0.90 ± 0.053 0.86 ± 0.038 2.850 0.064 – – 0.006**
Speaking turn duration 8.7 ± 1.54 7.2 ± 1.90 10.8 ± 1.37 0.684 0.508 – – –
Percentage of time speaking 69.2 ± 1.98 70.0 ± 2.45 77.3 ± 1.76 4.999 0.009** – 0.029* 0.004**
MLU 13.4 ± 1.37 16.8 ± 1.69 19.1 ± 1.22 6.539 0.002** – – 0.003**
TTR 0.20 ± 0.008 0.17 ± 0.009 0.16 ± 0.007 7.038 0.002** 0.019* – <0.0001**
Clauses per utterance 0.568 ± 0.005 0.572 ± 0.006 0.588 ± 0.004 0.783 0.461 – 0.049* 0.002**
Noun verb ratio 0.72 ± 0.017 0.69 ± 0.021 0.68 ± 0.015 0.649 0.526 – – –
Open–closed ratio 0.85 ± 0.014 0.82 ± 0.017 0.82 ± 0.012 0.424 0.656 – – –
Percentage of disfluencies 6.3 ± 0.52 6.2 ± 0.65 5.2 ± 0.47 1.496 0.231 – – –
Pause to word ratio 13.4 ± 0.77 11.3 ± 0.95 9.9 ± 0.68 4.033 0.022* – – 0.001**
Table displays estimates of means, covariates included in the model: age, sex and years of education.
High D2R schizophrenia patients with high dopamine D2 receptor medication, low D2R schizophrenia patients with low dopamine D2 receptor medication, HC
healthy controls, SE standard error, vs versus, MLU mean length of utterance, TTR type-token ratio. For explanation of the language variables, see Table 1.
*Significant at the level of α = 0.05.
**Significant at the level of α = 0.01, p-values are Bonferroni corrected.
aOnly significant p-values are reported.
J.N.de Boer et al.
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medication. Further studies should acknowledge that the use of
antipsychotic medication can influence their analyses.
In conclusion, we demonstrate that schizophrenia patients that
use high D2R occupancy drugs (e.g. aripiprazole) have more
severe language disturbances compared to patients that use low
D2R occupancy drugs (e.g. olanzapine, quetiapine) and healthy
controls, irrespective of the severity of their psychotic symptoms.
Our results indicate that language disturbances are better treated
by low D2R occupancy drugs, or that some language disturbances
might (in part) be caused by dopaminergic effects of high D2R
occupancy drugs. Language disturbances are common and greatly
impact social and functional outcome and quality of life in
schizophrenia. Further research is needed to evaluate possible
iatrogenic effects of medication on spoken language.
METHODS
Participants
A total of 81 participants, 41 patients with a schizophrenia spectrum
disorder and 40 healthy controls were included at the University Medical
Center Utrecht. Healthy controls were screened for previous or current
mental illness using the Comprehensive Assessment of Symptoms and
History (CASH)67 by a neuropsychologist. Patients were diagnosed by their
treating psychiatrist; the diagnosis was confirmed using the outcome of
the CASH or the Mini International Neuropsychiatric Interview 5.0.0. (M.I.N.I.
Plus)68 by the first author or a neuropsychologist and a second rater for
consensus diagnosis. Participants were included if they were (1) age
eighteen or above and (2) a native speaker of Dutch. Bilingual participants
were included if Dutch was (one of) their main language(s). An additional
inclusion criterion for patients was the presence of a DSM-IV diagnosis of:
295.x (schizophrenia, schizophreniform disorder, schizoaffective disorder)
or 298.9 (psychotic disorder NOS). General exclusion criteria were the
presence of uncorrected hearing disabilities or speech impediments (such
as stutter). Healthy controls were excluded in case of any current or
previous mental illness, or a family history of psychotic symptoms. The
severity of psychotic symptoms was assessed in all patients with the
PANSS69. This study was reviewed and admitted by the Ethical Review
Board of the University Medical Center Utrecht. Written informed consent
was obtained from all participants. Participants received a small monetary
award (ten euros).
Language data acquisition and processing
To elicit spontaneous speech we (J.B., A.V. and trained research assistants)
conducted semi-structured interviews varying from five to thirty minutes in
length (average fourteen minutes). Participants were informed that the
research involved the analysis of “general experiences”; only after
completion of the interview were they told that the research also focuses
on the way they speak. The interviews took place between December 2015
and March 2018.
A set of questions was used in the interview to control for potential
variations in language due to the topic that was discussed. All questions
concerned ‘neutral’ general life experiences; topics that could be expected
to have markedly different emotional valence for patients and healthy
controls were not addressed. For instance, topics such as “quality of life” or
“health” were avoided. If for any reason a subject did not want to answer a
question, the interviewer would move on to the next question. For a list of
the questions, see supplementary Table 1.
An AKG-C544l head-worn cardioid microphone was used to record the
subject’s speech. The first 39 interviews were conducted using a single
AKG-C544l head-worn cardioid microphone, worn by the subject,
recording both the interviewer’s and the subject’s speech onto a single
channel. A second AKG-C544l head-worn cardioid microphone was used
for the last interviews, resulting in a separate track for the subject and the
Table 4. Regression analyses of predictors of language disturbances in schizophrenia patients.




β Adjusted R2 p-value (uncorr.) p-value (FDR corr.)
1. Articulation rate PANSS positive 0.067 0.003 0.132 0.299 0.298 0.002** 0.004**
PANSS negative −0.069 −0.120 −0.017 −0.380
D2R occupancy −0.359 −0.659 −0.059 −0.342
2. Pause duration D2R occupancy 0.089 0.010 0.167 0.380 0.114 0.049* 0.055
Dosage (mg)a 0.0002 −0.00002 0.0005 0.304
3. Speaking turn duration PANSS positive 0.917 0.386 1.447 0.510 0.239 0.001** 0.002**
4. Percentage of time speaking PANSS negative −1.178 −1.664 −0.692 −0.574 0.539 <0.0001** <0.0001**
PANSS general 0.626 0.210 1.043 0.356
D2R occupancy −6.525 −9.302 −3.748 −0.547
5. MLU PANSS negative −0.498 −0.911 −0.085 −0.348 0.282 0.001** 0.003**
D2R occupancy −3.988 −6.384 −1.593 −0.480
6. TTR PANSS negative 0.003 0.0005 0.005 0.333 0.407 <0.0001** <0.0001**
PANSS general −0.003 −0.004 −0.001 −0.412
D2R occupancy 0.025 0.013 0.037 0.558
7. Clauses per utterance D2R occupancy −0.008 −0.017 −0.00001 −0.325 0.080 0.050 0.050
8. Open–closed ratio PANSS negative 0.006 0.002 0.009 0.442 0.215 0.006** 0.009**
D2R occupancy 0.022 −0.001 0.044 0.294
9. Pause to word ratio PANSS negative 0.261 0.042 0.481 0.360 0.206 0.008** 0.010**
D2R occupancy 1.598 0.322 2.875 0.380
The table displays unstandardized (B) and standardized (β) regression coefficient for each significant predictor, in a model for each of the language variables.
The adjusted R2 and ANOVA p-values display the fit and significance of the full model. Predictors entered into the model were: PANSS positive, negative and
general, D2R occupancy and chlorpromazine equivalent dose.
PANSS positive and negative syndrome scale, D2R dopamine D2 receptor, FDR false discovery rate, uncorr. uncorrected, corr. corrected, MLU mean length of
utterance, TTR type-token ratio.
*indicates significance at the level of α = 0.05.
**indicates significance at the level of α = 0.01, No significant relations were found between PANSS and medication and noun verb ratio and percentage of
disfluencies.
aChlorpromazine equivalent dose.
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interviewer. Speech was digitally recorded onto a Tascam DR40 solid-state
recording device at a sampling rating of 44,100 kHz with 16-bit
quantization.
The digitized recordings were analyzed using the Praat software70,
which is standardly used for acoustic analyses of speech. Speakers’ speech
signals were separated by hand onto two different tiers by J.B. and A.V. (i.e.
two audio tracks were created, one for the participant and one for the
interviewer). Each segment of speech was coded as belonging either to the
participant or the interviewer. When both speakers spoke at the same time,
that speech segment was coded as belonging to both speakers. The pause
that arises with switching between speakers was attributed to the speaker
following the pause. All speech segments of individual participants were
recombined into new audio files, which each thus contained only the
recording(s) of an individual participant’s speech, including pauses and
other interruptions. Data files were blinded for diagnosis to prevent bias in
separating the speaker. Inter-rater reliability for tier separation was
assessed by having both raters perform tier separation for two of the
files. Linguistic variables were then calculated for both audio files
individually, after which intraclass-correlation-coefficients were calculated
to assess the similarity in outcome measures for the different raters (which
was 97.7 percent). All files were set to an average sound pressure level of
60 dB to avoid differences in the analyses based on speaking volume.
The ‘Praat Script Syllable Nuclei v2’71 was used to automatically obtain
speech and articulation rates. The output of this script includes the following
raw numbers: total number of syllables and total number of pauses. Pauses
were defined as silences longer than 200ms, since shorter silences in speech
can still be related to the articulation of sounds such as plosives (e.g. the /p/,
which introduces a short silence in the sound wave)72. The raw measures
were calculated as a percentage of the duration of the participants’ audio
track, since they are strongly dependent on the length of the interview. The
participants’ audio file was transcribed using CLAN software according to the
CHILDES manual73. In CLAN, the EVAL and FLUCALC functions were used to
extract a collection of measures that reflect a person’s linguistic fluency and
complexity, such as total number of words used, TTR, open–closed ratio (i.e.,
a ratio of content words versus function words) as well as pausing and
disfluencies (see Fig. 1 and Table 1)74.
Classification of antipsychotic medication
Patients were asked to bring a current list of the medication they used. The
antipsychotic drugs were classified into different categories based on their
mechanism of action. Drugs such as clozapine and quetiapine bind more
loosely to the D2R than dopamine itself28. By contrast, typical antipsycho-
tics such as haloperidol and risperidone are strong D2R antagonists since
they bind more tightly to the receptor, which leads to higher receptor
occupancy by the drug. Aripiprazole is also categorized as a strong D2R
antagonist, although it also has some agonistic effects based on the cell
type59. Patients were divided into two categories based on these different
dopamine binding profiles, namely patients with (1) low D2R occupancy
drugs (i.e. quetiapine, paliperidone, olanzapine and clozapine) or (2) high
D2R occupancy drugs (i.e. aripiprazole, risperidone, flupentixol, amisul-
pride, and haloperidol)75–77. Antipsychotic drug dosages were recalculated
into chlorpromazine equivalents to evaluate the effect of dosage between
the drugs78.
Data analysis
All analyses were performed in IBM SPSS Statistics version 25.0 for
Windows. Participant characteristics were compared between groups
using an analysis of variance (ANOVA) for continuous values, and a χ2 test
for categorical values. To assess both the effect of antipsychotic
medication and symptom severity, the following analyses were performed.
(1) Between group (high D2R, low D2R and healthy controls) analysis of
language features was obtained through a multivariate analysis of
covariance (MANCOVA) by applying a general linear model (GLM). The
MANCOVA assumptions of linearity, normality and homoscedasticity were
checked visually by means of Q-Q plots and scatterplots of the residuals. P-
values were Bonferroni corrected to control for Type 1 errors. (2) To
investigate which language variables were associated with group
membership (patients with low versus high D2R drugs), a backward
binary logistic regression was performed. Predictors were the language
variables, as well as age, gender and education level. (3) To model the
effect of PANSS scores and the different types of antipsychotics (low versus
high D2R drugs) and dosage on the measures of language, MRAs were
performed. To account for possible biases due to multiple comparisons,
false discovery rate (FDR) was employed79.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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